[go: up one dir, main page]

NO2022004I1 - abrocitinib, or a pharmaceutically acceptable salt thereof - Google Patents

abrocitinib, or a pharmaceutically acceptable salt thereof

Info

Publication number
NO2022004I1
NO2022004I1 NO2022004C NO2022004C NO2022004I1 NO 2022004 I1 NO2022004 I1 NO 2022004I1 NO 2022004 C NO2022004 C NO 2022004C NO 2022004 C NO2022004 C NO 2022004C NO 2022004 I1 NO2022004 I1 NO 2022004I1
Authority
NO
Norway
Prior art keywords
abrocitinib
pharmaceutically acceptable
acceptable salt
salt
pharmaceutically
Prior art date
Application number
NO2022004C
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO2022004I1 publication Critical patent/NO2022004I1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
NO2022004C 2013-02-22 2022-02-01 abrocitinib, or a pharmaceutically acceptable salt thereof NO2022004I1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361767947P 2013-02-22 2013-02-22
PCT/IB2014/058889 WO2014128591A1 (en) 2013-02-22 2014-02-11 Pyrrolo [2, 3 -d]pyrimidine derivatives as inhibitors of janus- related kinases (jak)

Publications (1)

Publication Number Publication Date
NO2022004I1 true NO2022004I1 (no) 2022-02-01

Family

ID=50151346

Family Applications (2)

Application Number Title Priority Date Filing Date
NO14789648A NO3052752T3 (no) 2013-02-22 2014-09-24
NO2022004C NO2022004I1 (no) 2013-02-22 2022-02-01 abrocitinib, or a pharmaceutically acceptable salt thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO14789648A NO3052752T3 (no) 2013-02-22 2014-09-24

Country Status (47)

Country Link
US (3) US9035074B2 (no)
EP (2) EP2958921B1 (no)
JP (2) JP6145179B2 (no)
KR (1) KR101787858B1 (no)
CN (2) CN105008362B (no)
AP (1) AP2015008664A0 (no)
AR (1) AR094857A1 (no)
AU (1) AU2014220357B2 (no)
BR (1) BR112015019634B1 (no)
CA (1) CA2900703C (no)
CL (1) CL2015002303A1 (no)
CR (1) CR20150395A (no)
CU (1) CU24275B1 (no)
CY (3) CY1119502T1 (no)
DK (2) DK3290421T3 (no)
DO (1) DOP2015000206A (no)
EA (1) EA027879B1 (no)
ES (2) ES2647525T3 (no)
FR (1) FR22C1006I2 (no)
GE (1) GEP201606600B (no)
HK (1) HK1213881A1 (no)
HR (2) HRP20171599T2 (no)
HU (3) HUE037192T2 (no)
IL (1) IL240132B (no)
LT (3) LT2958921T (no)
MA (1) MA38347A1 (no)
MD (1) MD4735C1 (no)
ME (2) ME03301B (no)
MX (1) MX374338B (no)
MY (1) MY177476A (no)
NL (1) NL301155I2 (no)
NO (2) NO3052752T3 (no)
NZ (1) NZ710411A (no)
PE (1) PE20151764A1 (no)
PH (1) PH12015501779B1 (no)
PL (2) PL2958921T3 (no)
PT (2) PT3290421T (no)
RS (2) RS58245B1 (no)
SG (1) SG11201505816UA (no)
SI (2) SI3290421T1 (no)
TN (1) TN2015000355A1 (no)
TR (1) TR201902525T4 (no)
TW (1) TWI507408B (no)
UA (1) UA111804C2 (no)
UY (1) UY35337A (no)
WO (1) WO2014128591A1 (no)
ZA (1) ZA201505454B (no)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807419C (en) 2010-08-18 2019-09-24 Sunil Kumar Kc Diketones and hydroxyketones as catenin signaling pathway activators
EP2948134B1 (en) 2013-01-24 2020-03-04 Palvella Therapeutics, Inc. Compositions for transdermal delivery of mtor inhibitors
ME03301B (me) 2013-02-22 2019-07-20 Pfizer Kombinacija pirol0[2,3-d]pirimidinskih derivatas jednim ili više dodatnih sredstava као inhibitori kinaza srodnih janus kinazi (јак)
HUE042001T2 (hu) 2013-02-22 2019-06-28 Samumed Llc Gamma-diketonok Wnt/béta-katenin jelátviteli útvonal aktivátorokként
ES2750655T3 (es) 2014-08-12 2020-03-26 Pfizer Derivados de pirrolo[2,3-d]pirimidina útiles para inhibir la Janus cinasa
ES2762559T3 (es) 2014-08-20 2020-05-25 Samumed Llc Gamma-dicetonas para tratamiento y prevención de envejecimiento de la piel y arrugas
AU2016271904B2 (en) * 2015-05-29 2018-05-10 Wuxi Fortune Pharmaceutical Co.,Ltd Janus kinase inhibitor
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
AU2016340167B2 (en) 2015-10-16 2021-06-24 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CN106831779B (zh) * 2015-11-28 2019-07-19 南昌弘益药业有限公司 一类jak激酶抑制剂的新化合物
JP7096592B2 (ja) 2016-02-16 2022-07-06 ワシントン・ユニバーシティ Ｊａｋ阻害剤およびこれらの利用
JP7108631B2 (ja) 2017-01-06 2022-07-28 パルヴェラ セラピューティクス、インク． ｍＴＯＲ阻害剤の無水組成物およびその使用方法
CN108794480A (zh) * 2017-04-28 2018-11-13 天津药物研究院有限公司 吡咯并嘧啶类化合物、其制备方法和用途
ES2910071T3 (es) 2018-03-08 2022-05-11 Incyte Corp Compuestos de aminopirazina diol como inhibidores de PI3K-Y
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
WO2020010073A1 (en) 2018-07-02 2020-01-09 Palvella Therapeutics, Inc. ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE
CN112384282B (zh) * 2018-07-06 2024-07-02 辉瑞公司 吡咯并[2,3-d]嘧啶化合物的制造方法与中间体及其用途
JP2022506682A (ja) * 2018-11-05 2022-01-17 アビスタ ファーマ ソリューションズ，インコーポレーテッド 化合物
DK3915989T3 (da) * 2019-01-30 2023-09-18 Felicamed Biotechnology Co Ltd Jak inhibitor and preparation method therefor
JP7561497B2 (ja) 2019-02-15 2024-10-04 ファイザー・インク 結晶性ピリミジニル－３，８－ジアザビシクロ［３．２．１］オクタニルメタノン化合物およびその使用
EP3939979A4 (en) 2019-03-14 2022-04-06 Shanghai Synergy Pharmaceutical Sciences Co., Ltd KINASE JAK INHIBITOR, METHOD FOR PREPARING IT AND ITS APPLICATIONS IN THE FIELD OF MEDICINE
EP3989975A4 (en) * 2019-06-27 2023-09-27 Glenmark Life Sciences Limited METHOD FOR PRODUCING ABROCITINIB
AU2020347561A1 (en) * 2019-09-11 2022-04-14 Pfizer Inc. Treatment of hidradenitis with JAK inhibitors
AU2021248720A1 (en) 2020-04-04 2022-11-03 Pfizer Inc. Methods of treating coronavirus disease 2019
CN113637018A (zh) 2020-04-27 2021-11-12 苏州晶云药物科技股份有限公司 磺酰胺类化合物的晶型及其制备方法
MX2022014940A (es) * 2020-05-28 2023-01-04 Pfizer Derivados de pirrolo[2,3-d]pirimidina.
WO2022054006A1 (en) * 2020-09-11 2022-03-17 Galderma Holding SA Novel jak inhibitor compounds, method for synthesizing same and use thereof
WO2022167913A1 (en) 2021-02-02 2022-08-11 Pfizer Inc. Dosing regime for treatment of chronic hand eczema
WO2023014049A1 (ko) * 2021-08-02 2023-02-09 한국화학연구원 신규한 피롤로 피리미딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 대사성 간질환의 예방 또는 치료용 약학적 조성물
CN118255769A (zh) * 2022-12-28 2024-06-28 格格巫（珠海）生物科技有限公司 一种立体异构体的制备方法及中间体
ES2993658A1 (es) 2023-06-27 2025-01-03 Moehs Iberica Sl (3-(metil(7h-pirrolo[2,3-d]pirimidin-4-il)amino)ciclobutilo)carbamato de bencilo o una sal del mismo, procedimiento para su preparacion y su uso en la sintesis de abrocitinib
WO2025008772A2 (en) 2023-07-06 2025-01-09 Pfizer Ireland Pharmaceuticals Improved manufacturing process and intermediates for a pyrrolo[2,3-d]pyrimidine compound and use thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
JP2895961B2 (ja) 1992-12-17 1999-05-31 フアイザー・インコーポレイテツド Ｃｒｆアンタゴニストとしてのピロロピリミジン
JPH06329674A (ja) 1993-05-20 1994-11-29 Teijin Ltd ４―置換シクロヘキシルアミノ―ピロロ［２，３―ｄ］ピリミジン
JPH06329675A (ja) 1993-05-20 1994-11-29 Teijin Ltd ４―置換アルキルアミノ―ピロロ［２，３―ｄ］ピリミジン誘導体
JPH08134068A (ja) 1994-11-02 1996-05-28 Teijin Ltd ４―置換アルキルアミノ―ピロロ［２，３―ｄ］ピリミジン誘導体
US6051578A (en) 1996-02-12 2000-04-18 Pfizer Inc. Pyrazolopyrimidines for treatment of CNS disorders
US6686366B1 (en) 1998-06-02 2004-02-03 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
BR9911365A (pt) 1998-06-19 2001-03-13 Pfizer Prod Inc Compostos pirrolo[2,3-d]pirimidina
PA8474101A1 (es) 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
EP1040831A3 (en) 1999-04-02 2003-05-02 Pfizer Products Inc. Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death
AU4808300A (en) 1999-04-30 2000-11-17 Neurogen Corporation 9h-pyrimido(4,5-b)indole derivatives: crf1 specific ligands
US6664252B2 (en) 1999-12-02 2003-12-16 Osi Pharmaceuticals, Inc. 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
EA006227B1 (ru) 1999-12-10 2005-10-27 Пфайзер Продактс Инк. СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА
AU3540101A (en) 2000-01-07 2001-07-16 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
EE200200711A (et) 2000-06-26 2004-06-15 Pfizer Products Inc. Pürrolo[2,3-d]pürimidiinühendid kui immunosupressiivsed vahendid
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US6673802B2 (en) 2000-12-01 2004-01-06 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A3 receptor and uses thereof
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
DK1450811T3 (da) 2001-11-30 2010-02-15 Osi Pharm Inc Forbindelser specifikke af adenosin A1- og A3-receptorer og anvendelser heraf
US20030139427A1 (en) 2002-08-23 2003-07-24 Osi Pharmaceuticals Inc. Bicyclic pyrimidinyl derivatives and methods of use thereof
WO2004032834A2 (en) 2002-10-04 2004-04-22 Merck & Co., Inc. Thrombin inhibitors
RS20050380A (en) 2002-11-21 2007-11-15 Pfizer Products Inc., 3-amino piperidine derivatives and methods of manufacture
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
SI1913000T1 (sl) * 2005-07-29 2012-02-29 Pfizer Prod Inc Derivati pirolo(2,3-d)pirimidina; njihovi intermediati in sinteza
JP2007091649A (ja) 2005-09-29 2007-04-12 Taisho Pharmaceut Co Ltd ピリミジン誘導体及びその使用に関連する治療方法
GB0526246D0 (en) * 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP2007373A4 (en) 2006-03-29 2012-12-19 Foldrx Pharmaceuticals Inc INHIBITION OF ALPHA SYNUCLEINE TOXICITY
US20080194557A1 (en) 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
WO2008089310A2 (en) 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of obesity
EP2217239A2 (en) 2007-11-07 2010-08-18 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
JP2011503046A (ja) 2007-11-08 2011-01-27 ファイザー・インク シクロブチルカルボン酸誘導体
US8946239B2 (en) 2008-07-10 2015-02-03 Duquesne University Of The Holy Spirit Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
ME01269B (me) * 2008-08-20 2013-06-20 Zoetis Services Llc Jedinjenja pirolo (2,3-d) pirimidina
MX2011002899A (es) 2008-09-18 2011-04-11 Pfizer Ltd Compuestos de amida utiles en terapia.
CN102574860A (zh) * 2009-10-15 2012-07-11 辉瑞大药厂 吡咯并[2,3-d]嘧啶化合物
WO2011068881A1 (en) 2009-12-01 2011-06-09 Abbott Laboratories Novel tricyclic compounds
CA2782720A1 (en) * 2009-12-18 2011-06-23 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine compounds
CA2781578A1 (en) 2010-01-12 2011-07-21 F. Hoffmann-La Roche Ag Tricyclic heterocyclic compounds, compositions and methods of use thereof
BR112012020989A2 (pt) 2010-02-24 2016-05-03 Pfizer composições veterinárias
US20130184222A1 (en) 2010-07-16 2013-07-18 Agios Pharmaceuticals, Inc Therapeutically active compositions and their methods of use
WO2012009649A1 (en) 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses
EP2646444B1 (en) 2010-12-03 2016-03-16 Epizyme, Inc. Substituted purine and 7-deazapurine compounds as modulators of epigenetic enzymes
US8987307B2 (en) 2011-03-03 2015-03-24 Hoffmann-La Roche Inc. 3-amino-pyridines as GPBAR1 agonists
BR112013030939A2 (pt) 2011-06-07 2016-12-06 Dainippon Sumitomo Pharma Co derivado de indazol e pirrolopiridina e uso farmacêutico do mesmo
JP2013010719A (ja) 2011-06-30 2013-01-17 Dainippon Sumitomo Pharma Co Ltd ベンズイミダゾロンおよびオキシインドール誘導体ならびにそれらの医薬用途
KR102032934B1 (ko) * 2011-12-21 2019-10-16 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피롤 6원 헤테로아릴 고리 유도체, 그의 제조 방법, 및 그의 의약 용도
US20140018361A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
PL2874630T3 (pl) 2012-07-20 2019-04-30 Zoetis Services Llc Schemat dawkowania inhibitorów kinazy janusowej (JAK)
JP2014133739A (ja) 2012-12-12 2014-07-24 Dainippon Sumitomo Pharma Co Ltd インダゾール誘導体またはピロロピリジン誘導体からなる医薬
ME03301B (me) * 2013-02-22 2019-07-20 Pfizer Kombinacija pirol0[2,3-d]pirimidinskih derivatas jednim ili više dodatnih sredstava као inhibitori kinaza srodnih janus kinazi (јак)
ES2750655T3 (es) 2014-08-12 2020-03-26 Pfizer Derivados de pirrolo[2,3-d]pirimidina útiles para inhibir la Janus cinasa

Also Published As

Publication number Publication date
FR22C1006I1 (fr) 2022-03-25
ZA201505454B (en) 2016-07-27
CR20150395A (es) 2015-09-23
EA201591255A1 (ru) 2016-03-31
BR112015019634B1 (pt) 2022-09-20
US20150225408A1 (en) 2015-08-13
MD20150073A2 (ro) 2016-01-31
DK2958921T3 (da) 2017-11-06
MA38347A1 (fr) 2017-10-31
BR112015019634A2 (pt) 2019-12-17
CA2900703C (en) 2017-11-28
TWI507408B (zh) 2015-11-11
MX374338B (es) 2025-03-06
HRP20171599T1 (hr) 2017-12-01
CY1119502T1 (el) 2018-03-07
EP3290421A1 (en) 2018-03-07
MD4735C1 (ro) 2021-07-31
CN105008362B (zh) 2017-06-06
PE20151764A1 (es) 2015-12-03
RS58245B1 (sr) 2019-03-29
TR201902525T4 (tr) 2019-03-21
CY2022003I1 (el) 2022-03-24
CY2022003I2 (el) 2022-03-24
AU2014220357A1 (en) 2015-08-06
NZ710411A (en) 2017-11-24
CL2015002303A1 (es) 2015-12-18
ME02904B (me) 2018-04-20
JP6145179B2 (ja) 2017-06-07
SG11201505816UA (en) 2015-09-29
PH12015501779A1 (en) 2015-12-02
JP2016509049A (ja) 2016-03-24
WO2014128591A1 (en) 2014-08-28
HUS2200003I1 (hu) 2022-02-28
AR094857A1 (es) 2015-09-02
HUE037192T2 (hu) 2018-08-28
MD4735B1 (ro) 2020-12-31
IL240132B (en) 2020-09-30
KR101787858B1 (ko) 2017-10-18
RS56503B1 (sr) 2018-02-28
DK3290421T3 (en) 2019-03-18
DOP2015000206A (es) 2016-02-15
IL240132A0 (en) 2015-09-24
HK1213881A1 (zh) 2016-07-15
EP2958921A1 (en) 2015-12-30
TN2015000355A1 (fr) 2017-01-03
MY177476A (en) 2020-09-16
SI2958921T1 (sl) 2017-12-29
PH12015501779B1 (en) 2015-12-02
FR22C1006I2 (fr) 2023-01-27
US20150246048A1 (en) 2015-09-03
CU20150078A7 (es) 2016-01-29
NL301155I1 (no) 2021-12-22
TW201443055A (zh) 2014-11-16
AP2015008664A0 (en) 2015-08-31
CN105008362A (zh) 2015-10-28
CA2900703A1 (en) 2014-08-28
JP2017165762A (ja) 2017-09-21
ME03301B (me) 2019-07-20
NO3052752T3 (no) 2018-06-16
CN107089985B (zh) 2019-06-07
UA111804C2 (uk) 2016-06-10
HRP20190152T1 (hr) 2019-03-22
US9035074B2 (en) 2015-05-19
US9545405B2 (en) 2017-01-17
MX2015010928A (es) 2015-10-29
US9549929B2 (en) 2017-01-24
LT3290421T (lt) 2019-02-25
ES2713052T3 (es) 2019-05-17
AU2014220357B2 (en) 2017-04-27
PL2958921T3 (pl) 2018-01-31
UY35337A (es) 2014-09-30
HRP20171599T2 (hr) 2018-11-16
NL301155I2 (nl) 2022-02-23
PT2958921T (pt) 2017-11-20
CN107089985A (zh) 2017-08-25
EA027879B1 (ru) 2017-09-29
SI3290421T1 (sl) 2019-03-29
LT2958921T (lt) 2017-11-27
PL3290421T3 (pl) 2019-05-31
ES2647525T3 (es) 2017-12-22
KR20150109434A (ko) 2015-10-01
GEP201606600B (en) 2017-01-10
EP3290421B1 (en) 2019-01-02
LTPA2022502I1 (no) 2022-03-10
CY1121468T1 (el) 2020-05-29
CU24275B1 (es) 2017-10-05
EP2958921B1 (en) 2017-09-20
PT3290421T (pt) 2019-03-01
US20140243312A1 (en) 2014-08-28
HUE041778T2 (hu) 2019-05-28

Similar Documents

Publication Publication Date Title
NO2024001I1 (no) Ritlecitinib, or a pharmaceutically acceptable salt thereof
NO2022004I1 (no) abrocitinib, or a pharmaceutically acceptable salt thereof
NO2024042I1 (no) Iptacopan or a pharmaceutically acceptable salt thereof
NO2023043I1 (no) Mavacamten or a pharmaceutically acceptable salt thereof
NO2022005I1 (no) Zanubrutinib or a pharmaceutically acceptable salt thereof
NO2022010I1 (no) ripretinib, or a pharmaceutically acceptable salt thereof
NO2021034I1 (no) pemigatinib or a pharmaceutically acceptable salt thereof
NO2021035I1 (no) Risdiplam or a pharmaceutically acceptable salt thereof
NO2021041I1 (no) remimazolam or a pharmaceutically acceptable salt thereof
NL301286I2 (nl) Danicopan, of een farmaceutisch aanvaardbaar zout ervan
NO2022044I1 (no) daridorexant eller et farmasøytisk akseptabelt salt derav, spesielt daridorexant hydroklorid
NO2022009I1 (no) Lumasiran, optionally in the form of a salt
NL301149I2 (nl) setmelanotide, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
LUC00083I2 (en) Bictegravir or a pharmaceutically acceptable salt thereof, in particular bictegravir sodium
NO2024009I1 (no) Gefapixant, or a pharmaceutically acceptable salt thereof
NO2020029I1 (no) Givosiran eller et farmasøytisk akseptabelt salt derav
NO2022058I1 (no) Capmatinib or a pharmaceutically acceptable salt thereof
HUE037275T2 (hu) Gyógyszer-kombináció
BR302014001381S1 (pt) Configuração aplicada em bolsa.
ZA201603624B (en) Urea derivative or pharmacologically acceptable salt thereof
HUE045209T2 (hu) Aramchol-sók
DK2975030T3 (da) Dihydropyridazin-3,5-dion-derivat
FR3010437B1 (fr) Serrure a mortaiser reglable
PT2980085T (pt) Compostos farmaceuticamente activos
FI20135236A (fi) Haudutin